Loading market dashboard
The Obesity ETF
SLIMFinancial ServicesNASDAQ
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
HONG KONG, June 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes Association (ADA) 2026 Scientific Sessions (taking place June 5-8, 2026, in New Orleans, Louisiana), highlighting its differentiated portfolio in obesity treatment, including small-molecule candidates, a peptide therapeutic, and an oral peptide delivery-enhancing technology. The data attracted considerable interest from leading experts at the meeting and further underscored Ascletis' innovation capabilities in metabolic disease therapeutics.
Publication presented concurrently with oral presentation at American Diabetes Association's 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist
CAMBRIDGE, Mass., June 4, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H.
Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health and Metabolic Outcomes Late-Breaking Preclinical Findings at the American Diabetes Association Annual Meeting June 5-8 Highlighting Potential Mechanisms through which Icovamenib may Support Metabolic Health SAN CARLOS, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced a collaboration with the University of Leicester as part of the ongoing platform research study titled Investigating and Optimizing Physical Function with Weight Loss: A Multi-Arm Open Label Adaptive Platform Trial (OPAL) which is being led by Professors Melanie Davies and Thomas Yates at the University of Leicester and Leicester Diabetes Centre (LDC).
Rhythm Pharmaceuticals is transitioning from a development stage to a commercial rare disease leader, leveraging its IMCIVREE franchise for biologically defined obesity. IMCIVREE's recent FDA and EU approvals for acquired hypothalamic obesity unlock a significant, underserved market with rapid early uptake and global expansion potential. RYTM's premium valuation is justified by rapid revenue growth, multiple approved indications, global infrastructure, and a robust pipeline targeting rare neuroendocrine obesity.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that new data from its obesity portfolio will be presented at the 2026 Scientific Sessions of the American Diabetes Association® (ADA). The insights demonstrate significant progress in addressing a range of unmet needs for people living with obesity or overweight such as long-term treatment adherence, which could be supported by a favorable safety and tolerability p.
48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of Plateau Exploratory FibroScan Assessments Demonstrated Early Liver-Related Improvements Ongoing Phase 1 Part 3a/3b Titration Studies Continue to Evaluate Extended Treatment at Higher-Dose Levels CAMBRIDGE, Mass., May 27, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of new Phase 1 data on DA-1726, a novel dual oxyntomodulin (OXM) analog agonist targeting glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR), in a late-breaking poster presentation at the European Association for the Study of the Liver Congress 2026 (EASL 2026), being held May 27–30 in Barcelona, Spain.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented interim results from a Phase 1/2a clinical trial of ARO-INHBE, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity and metabolic dysfunction-associated steatohepatitis (MASH). The data presented at the European Association for the Study of the Liver Congress (EASL 2026) demonstrate that ARO-INHBE treatment led to clinically meaningf.
NVO's Wegovy pill gets CHMP backing, moving it closer to becoming the first oral GLP-1 treatment approved in the EU for weight management.
Corbus Pharmaceuticals NASDAQ: CRBP Chief Executive Officer Yuval Cohen said investors should expect more mature clinical updates for CRB-701 at the upcoming ASCO meeting, including the first durability and progression-free survival data for the company's highlighted cervical and head and neck cancer cohorts.
Patients lost up to 85 pounds in a study of Eli Lilly's next-generation weight-loss drug, the company said Thursday.
Three Late-Breaking Posters Highlight DA-1726, a GLP-1/Glucagon Dual Agonist, and Vanoglipel, a GPR119 Agonist CAMBRIDGE, Mass., May 18, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that three late-breaking abstracts highlighting its cardiometabolic assets, DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors for the treatment of obesity, and vanoglipel (DA-1241), a novel G-protein-coupled receptor 119 (GPR119) agonist, have been accepted for poster presentations at the American Diabetes Association's (ADA) 2026 Scientific Sessions.
FORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company's investigational oral metabolic therapeutic candidate.
LLY expands beyond tirzepatide with oral obesity pills and next-gen drugs like retatrutide to defend its lead in the booming weight-loss market.
SAN FRANCISCO and SUZHOU, China, May 12, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that it will present multiple clinical and preclinical data from mazdutide and its next‑generation obesity and metabolic pipeline at the 2026 American Diabetes Association's® (ADA) Scientific Sessions, to be held in New Orleans, U.S. from June 5–8, 2026. Dr. Lei Qian, Chief R&D Officer (General Biomedicine) of Innovent, stated, "At this year's ADA Scientific Sessions, we are pleased to present a series of new data in obesity and metabolic diseases, which is an important step in establishing Innovent as an emerging leader and innovator in this field.
Wegovy® showed an average 22.6% weight loss for premenopausal women with obesity, with more than 4 in 10 (41.4%) achieving 25% or more weight loss1. Substantial weight loss was consistent across all menopausal stages, as well as major reductions in waist circumference, a key indicator of metabolic health1.
Early responders (15% or more weight loss after 24 weeks) to the higher dose of Wegovy ® (semaglutide 7.2 mg) achieved on average 27.7% mean weight loss at week 72 in the STEP UP trial1 Participants treated with the higher dose of Wegovy ® reached weight loss goals faster as compared to semaglutide 2.4 mg1 The majority of the weight loss comes from losing body fat: 84% of weight loss with Wegovy ® (semaglutide 2.4 and 7.2 mg) can be attributed to reductions in fat mass, while preserving muscle function and improving muscle health2 Bagsværd, Denmark, 12 May 2026 – Novo Nordisk is presenting a new sub-analysis from the large clinical trial STEP UP at the European Congress on Obesity (ECO) on 12-15 May in Istanbul, Türkiye, showing that the higher dose of the weight loss drug Wegovy ® is highly effective at helping people with obesity lose significant amounts of weight regardless of how quickly their body responds to the treatment1. Moreover, a separate STEP UP sub-analysis presented at ECO shows that most of the weight loss with Wegovy ® was coming from body fat, and most of the muscle mass was kept2.
Healthcare is regaining momentum as innovation—especially AI‑driven drug discovery—creates new growth opportunities, according to Shivani Vohra. She points to obesity treatments from Eli Lilly (LLY) and Novo Nordisk (NVO), advances in diagnostics from Natera (NTRA), and continued strength in med tech leaders like Intuitive Surgical (ISRG) and Edwards Lifesciences (EW) as key areas of expansion.
Eli Lilly's Zepbound is already generating billions of dollars in revenue, making it the clear leader in a rapidly expanding market. Lilly's ability to produce and deliver creates a hurdle that smaller competitors can't easily overcome.
HONG KONG, May 5, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the 33rd European Congress on Obesity (ECO 2026), taking place May 12-15, 2026 in Istanbul, Türkiye. The presentations include a poster on the Phase I data of ASC47, an adipose-targeting thyroid hormone receptor beta (THRβ) agonist for muscle-preserving weight loss, which, in combination with semaglutide, demonstrated up to 111.8% greater relative weight loss in participants with obesity compared to semaglutide monotherapy, and a poster on the preclinical data of ASC36, a once-monthly next-generation amylin receptor agonist peptide, which demonstrated 32-day average observed half-life, 6-fold longer than petrelintide, in non-human primate (NHP) model and 91% more relative weight loss than petrelintide in diet-induced obese (DIO) rat model.
-- Pediatric patients (n=10) with acquired hypothalamic obesity achieved sustained reductions in BMI and BMI-Z at 2.5 years of setmelanotide therapy -- -- Weight category improvements observed in pediatric patients with acquired hypothalamic obesity treated with setmelanotide -- BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the presentation of new data to be delivered by Rhythm and its partners at The Pediatric Endocrine Society (PES) Annual Meeting, taking place April 30-May 3, 2026, in San Francisco. “Acquired hypothalamic obesity is a complex disease that requires long-term management, particularly in pediatric patients,” said Jennifer Miller, M.D.
-- First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity -- -- European Commission grants authorization in adults and children 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment --
Analyses of the higher dose of Wegovy® (semaglutide 7.2 mg) and Wegovy® pill (oral semaglutide 25 mg) show how fast and how much sustained weight loss people who responded early to treatment achieved Wegovy® (semaglutide 2.4 mg and 7.2 mg) clinical and real-world data exploring its role in managing menopausal symptoms, including weight gain and migraine, and lowering cardiovascular risk Data on next-generation obesity pipeline, including the advanced combined amylin and GLP-1 receptor analogues Bagsværd, Denmark, 28 April 2026 – Novo Nordisk will present new clinical data and real-world evidence at the European Congress on Obesity, 12–15 May in Istanbul, Turkey. The full data, 52 abstracts, span Wegovy® (semaglutide 2.4 mg), higher-dose Wegovy® (semaglutide 7.2 mg), Wegovy® pill (oral semaglutide 25 mg), and CagriSema (cagrilintide 2.4 mg/semaglutide 2.4 mg), an investigational first-in-class combination of a GLP-1 receptor agonist and a long-acting amylin analogue.
Although now mature, the weight-loss drug market remains strong and growing. The top GLP-1 drug competitors were first to market, but not racing to the finish line has given some drug developers more time to develop a more marketable alternative.
Reuters, citing IQVIA data, reported that Eli Lilly recorded 1,390 prescriptions for its newly launched obesity pill in the U.S. for the week ended April 10.
Viking Therapeutics aims to participate in the billion-dollar obesity market. The company's most advanced candidate is in a phase 3 trial.
Biohaven Ltd. is downgraded from Strong Buy to Hold following the FDA's Complete Response Letter for troriluzole in Spinocerebellar Ataxia. BHVN pivots focus to three late-stage programs: MODE/TRAP degraders [BHV-1400, BHV-1300], Kv7 activator Opakalim, and myostatin-activin inhibitor taldefgrobep alfa for obesity. Taldefgrobep alfa targets obesity with a novel MOA aiming for fat loss, muscle gain, and improved safety versus GLP-1s; phase 2 POC data is expected in 2H 2026.
Eli Lilly's newer weight-loss medicines will help cement its dominance in the market. The company could ride this tailwind through the medium term and deliver strong returns.
Eli Lilly and Company (NYSE:LLY | LLY Price Prediction) and Novo Nordisk A/S (NYSE:NVO) reported quarterly results in early February, and the gap between them has widened significantly.
Structure Therapeutics (GPCR) is initiated with a BUY rating and $110 price target, reflecting a 101% upside from current levels. Aleniglipron, GPCR's oral GLP-1 agonist, demonstrated 16.3% placebo-adjusted weight loss at 44 weeks with superior safety and manufacturing cost advantages. GPCR's $1.4B cash position provides runway through 2028 and a valuation floor of $23.10 in a bear scenario.
The rising popularity of GLP-1 drugs is a big reason why investors are bullish on the anti-obesity market. GLP-1 drugs, however, need to be taken on an ongoing basis and come with risks.
LLY wins FDA nod for oral obesity pill Foundayo, boosting shares as it eyes billions in sales and a fast catch-up to rivals in the booming GLP-1 market.
Foundayo (orforglipron) has a serious advantage over Novo Nordisk's Wegovy pill. Retatrutide, a subcutaneous triple hormone receptor agonist in phase 3 trials, could be a game changer.
Jamey Millar, executive vice president, US Operations of Novo Nordisk, reacts to Eli Lilly's once-daily weight-loss pill, called Foundayo, winning FDA approval on "Bloomberg The Close." -------- More on Bloomberg Television and Markets Like this video?
Eli Lilly stock jumped midday Wednesday after the Food and Drug Administration approved its weight-loss pill, now called Foundayo.
Dallas, TX, March 31, 2026 (GLOBE NEWSWIRE) -- PatentVest today released its latest PatentVest Pulse report, “The Amylin Renaissance: Forty Programs, $19 Billion in Deals, and the Race to Build the Next Pillar of Obesity Medicine.”
EXTON, Pa., March 31, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today the opening of its new building at its current site in Damastown, Dublin. The 165,000 square foot expansion significantly enhances West's contract services and is designed to meet growing global demands of its customers' high-volume treatments, including diabetes and obesity.
The company is trying to win customers by offering a “lower, predictable monthly price” for its obesity drugs.
Wave Life Sciences (NASDAQ:WVE) shares are trading near historic lows after two Wall Street firms cut their price targets following updated Phase 1 INLIGHT trial data for WVE-007, the company's obesity candidate.
Expand NASDAQ: WVE Wave Life Sciences Today's Change (-49.84%) $-6.13 Current Price $6.17 Key Data Points Market Cap $2.3B Day's Range $5.04 - $6.48 52wk Range $5.04 - $21.73 Volume 1.5M Avg Vol 3.3M Gross Margin 79.28% Wave Life Sciences (WVE 49.84%), developer of RNA medicines for rare genetic diseases, closed Thursday at $6.20, down 49.59% for the session. The stock sank after disappointing higher-dose WVE-007 obesity data underperformed the lower dose.
-- European Commission decision anticipated in second quarter of 2026 -- BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending to expand the current marketing authorization for IMCIVREE® (setmelanotide) to include the treatment of obesity and the control of hunger in adults and children 4 years of age and above with acquired hypothalamic obesity (HO) due to hypothalamic injury or impairment.
— QSIVA offers clinically meaningful weight loss supported by a well-established safety profile, now available at a reduced price across Nordics and Poland
The drugmaker said UBT251 achieved mean body weight reduction of up to 9.8% after a 24-week trial.
The study is investigating the safety and tolerability of LX9851, how it moves through the body and its physiological and biological impacts.
Despite HSBC downgrading Eli Lilly and Company stock, it remains my favorite in the obesity treatment market. That's also because LLY's tirzepatide franchise sales grew 114.6% year-on-year to about $11.7 billion in Q4. Meanwhile, on March 19, Eli Lilly published promising clinical data on retatrutide for the treatment of type 2 diabetes.
Rhythm Pharmaceuticals stock popped Friday after the FDA signed off on its obesity drug for patients with a rare, hunger-spiking disease.
NVO wins FDA's accelerated nod for a higher 7.2 mg Wegovy dose, backed by strong phase III weight-loss data, with a U.S. launch planned for April 2026.
-- First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfunction –
Phase 2 study in obesity, evaluating treatment with once-weekly and once-monthly taldefgrobep alfa as monotherapy, is now fully enrolled; topline data expected in 2H 2026. Taldefgrobep is a novel inhibitor of the myostatin-activin signaling pathway, which directly targets both fat and muscle, offering the potential to achieve high-quality weight loss in people living with overweight and obesity.
According to Bloomberg, the downgrade (the stock's lowest on Wall Street) comes after a bit of back and forth.
Eli Lilly (NYSE:LLY) stock is down 5% in Tuesday afternoon trading, with shares falling to $937 from a prior close of $989.12.
Eli Lilly And Co ( NYSE:LLY) stock is down 2.2% to trade at $967.06 at last glance, after a downgrade at HSBC "reduce" from "hold.
Strengthens global IP and supports strategic positioning in the rapidly growing metabolic therapeutics market Ramat Gan, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that the Israeli Patent Office has allowed its patent application No.
Eli Lilly and Co (NYSE: LLY) on Thursday issued a public warning about potential safety risks linked to compounded tirzepatide products that are mixed with vitamin B12.
PONTE VEDRA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thrombotic conditions, today highlighted recent scientific findings demonstrating the potential of its first-in-class 12-lipoxygenase (12-LOX) inhibitor, CAD-1005, to target inflammatory consequences of obesity and Type 2 diabetes.
